资源类型：
期刊/会议
文章类型：
会议摘要
作者：
Hirsh, V.[1]
;
Tan, E.[2]
;
Wu, Y.[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24]
;
Sequist, L.[3,4]
;
Zhou, C.[5]
;
Schuler, M.[6]
;
Geater, S.[7]
;
Mok, T.[8]
;
Hu, C.[9]
;
Yamamoto, N.[10]
;
Feng, J.[11]
;
O'Byrne, K.[12,13]
;
Lu, S.[14]
;
Huang, Y.[15]
;
Sebastian, M.[16]
;
Okamoto, I.[17]
;
Dickgreber, N.[18]
;
Shah, R.[19]
;
Palmer, M.[20]
;
Maerten, A.[21]
;
Massey, D.[22]
;
Samuelsen, C.[21]
;
Yang, J. C.[23,24]
;
机构：
[1]McGill Univ, Montreal, PQ, Canada
[2]Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore
[3]Massachusetts Gen Hosp, Boston, MA 02114 USA
[4]Harvard Med Sch, Boston, MA 02115 USA
[5]Tongji Univ, Shanghai Pulm Hosp, Shanghai, Peoples R China
[6]Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Essen, Germany
[7]Prince Songkla Univ, Hat Yai, Thailand
[8]Chinese Univ Hong Kong, Hong Kong Canc Inst, State Key Lab South China, Hong Kong, Peoples R China
[9]Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China
[10]Wakayama Med Univ, Wakayama, Japan
[11]Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China
[12]Princess Alexandra Hosp, Woolloongabba, Qld, Australia
[13]Queensland Univ Technol, Brisbane, Qld, Australia
[14]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Tumor Clin Med Ctr, Shanghai, Peoples R China
[15]Kunming Med Univ, Affiliated Hosp 3, Yunnan Tumor Hosp, Kunming, Yunnan, Peoples R China
[16]Goethe Univ Frankfurt, Med Ctr, Frankfurt, Germany
[17]Kyushu Univ, Grad Sch Med Sci, Res Inst Dis Chest, Fukuoka, Fukuoka, Japan
[18]Mathias Spital Rheine, Thorac Oncol & Resp Care Med, Rheine, Germany
[19]Maidstone Hlth Author, Kent Oncol Ctr, Maidstone, Kent, England
[20]Manchester Metropolitan Univ, Sch Healthcare Sci, Manchester, Lancs, England
[21]Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[22]Boehringer Ingelheim Ltd Uk, Bracknell, Berks, England
[23]Natl Taiwan Univ Hosp, Taipei, Taiwan
[24]Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
ISSN：
1556-0864
关键词：
dose adjustment
PROs
afatinib
WOS：
WOS:000463860802115
中科院(CAS)分区：
出版当年[2017]版：
大类
|
2 区
医学
小类
|
2 区
肿瘤学
2 区
呼吸系统
最新[2023]版：
大类
|
1 区
医学
小类
|
1 区
肿瘤学
1 区
呼吸系统
第一作者：
Hirsh, V.
第一作者机构：
[1]McGill Univ, Montreal, PQ, Canada
推荐引用方式(GB/T 7714)：
Hirsh V.,Tan E.,Wu Y.,et al.Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm plus NSCLC[J].JOURNAL OF THORACIC ONCOLOGY.2017,12(11):S2231-S2231.doi:10.1016/j.jtho.2017.09.1516.
APA：
Hirsh, V.,Tan, E.,Wu, Y.,Sequist, L.,Zhou, C....&Yang, J. C..(2017).Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm plus NSCLC.JOURNAL OF THORACIC ONCOLOGY,12,(11)
MLA：
Hirsh, V.,et al."Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm plus NSCLC".JOURNAL OF THORACIC ONCOLOGY 12..11(2017):S2231-S2231
医学